What do systematic reviews say?

Loratadine 10 mg vs placebo (4‐week intervention)

• Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 28 participants
  Low

Loratadine 10 mg vs placebo (4‐week intervention)

Loratadine 10 mg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (4‐week intervention) (low certainty).

• Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
  RR 0.25 [0.01, 5.76]
  1 study · 28 participants
  Low

Loratadine 10 mg vs placebo (4‐week intervention)

• Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 28 participants
  Low

Loratadine 10 mg vs placebo (4‐week intervention)

The review found no eligible studies for this question.

• Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Loratadine 10 mg vs placebo (4‐week intervention)

The review found no eligible studies for this question.

• Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Loratadine 10 mg vs placebo (2‐week intervention)

• Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 71 participants
  Low

Loratadine 10 mg vs placebo (2‐week intervention)

• Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 73 participants
  GRADE not reported

Loratadine 10 mg vs placebo (2‐week intervention)

Loratadine 10 mg/d showed no clear difference in secondary outcome 1. Physician‐assessed clinical signs Number for… compared with placebo (2‐week intervention) (low certainty).

• Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
  RR 2.04 [0.99, 4.2]
  1 study · 73 participants
  Low

Loratadine 10 mg vs placebo (2‐week intervention)

The review found no eligible studies for this question.

• Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Loratadine 10 mg vs placebo (2‐week intervention)

The review found no eligible studies for this question.

• Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found